Amgen announced that the FDA has approved Avsola® (infliximab) for all Remicade® approved indications.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Dec 06, 2019
Amgen announced that the FDA has approved Avsola® (infliximab) for all Remicade® approved indications.
By Bioblast Editor | Dec 05, 2019
NeuClone announces results of Ph I trials of trastuzumab biosimilar, reporting the product successfully met primary and secondary endpoints.
By Bioblast Editor | Dec 04, 2019
Bio-Thera announces NMPA approval to commence Ph I trials of ustekinumab biosimilar.
By Bioblast Editor | Dec 04, 2019
Amgen and pharmacy benefit manager Abarca announce outcome based agreement for Enbrel®, under which Amgen will provide rebates to Abarca’s clients who start etanercept to treat RA but discontinue treatment after 3 months. This is the second outcome-based between Abar...
By Bioblast Editor | Dec 02, 2019
Alvotech and Kamada announce agreement to commercialise six biosimilar products in Israel. The first product is expected to be launched in Israel in 2022.
By Bioblast Editor | Dec 02, 2019
Mylan and Biocon announced the launch of Ogivri® in the US. This FDA-approved product was co-developed by Biocon Biologics and Mylan.
By Bioblast Editor | Nov 28, 2019
Amneal and Amgen settle patent dispute over filgrastim biosimilar. Notice of the settlement was approved by a US Federal Court, however no further details have been published. Amgen had filed the complaint against Amneal in March 2018, alleging infringement of a number of p...
By Bioblast Editor | Nov 27, 2019
Coherus and Amgen settle suit over adalimumab. Notice of the agreement has been approved by a US Federal Court, however no further details about the settlement have been published. This dispute arose when Amgen launched Amgevita® in Europe in 2018 (manufactured in the US), ...
By Bioblast Editor | Nov 27, 2019
Biocon announces its supplemental BLA (sBLA) for biosimilar pegfilgrastim has been approved by the FDA. This additional approval relates to FDA approval of Biocon’s subsidiary Biocon Biologics’ new manufacturing facility in Bengalaru.
By Bioblast Editor | Nov 26, 2019
Shanghai Henlius announces proposed trastuzumab biosimilar met primary endpoint in Phase III clinical trials.
SUBSCRIBE TO PEARCE IP